Face Transplants Promised Hope. Patients Were Put Through the Unthinkable

Twenty years after surgeons in France performed the world's first face transplant, the experimental field that procedure launched is now confronting a troubling record of patient deaths, buried negative data and a healthcare system that leaves recipients financially devastated and medically vulnerable.

About 50 face transplants have been performed globally since Isabelle Dinoire received her partial face graft at University Hospital CHU Amiens-Picardie in November 2005. A 2024 JAMA Surgery study reported five-year graft survival of 85% and 10-year survival of 74%, concluding that the procedure is 'an effective reconstructive option for patients with severe facial defects.' The study did not track psychological wellbeing, financial outcomes, employment status or quality of life. Roughly 20% of face transplant patients have died from rejection, kidney failure, or heart failure.

The anti-rejection medications that keep transplanted faces alive can destroy kidneys and weaken immune systems to the point where routine infections become life-threatening. In the United States, the Department of Defense has funded most operations, treating them as a frontier for wounded veterans, because private insurers refuse to cover the costs. Patients who survive the surgery often find themselves unable to afford medications, transportation to follow-up appointments or basic caregiving. The field's long-term grants cover surgical innovation but not the lifelong needs of the people who receive these transplants.

Read more of this story at Slashdot.